Trial reportLeukemia2004
Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma.
Trial report in Leukemia, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 96 citations in OpenAlex.
- Prognostic significance of serum proangiogenic molecules in patients with de novo non-Hodgkin lymphomas.TheScientificWorldJournal · 2012Trial
- Trial
- First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma.Bone marrow transplantation · 2005Trial
- The Impact of Endothelial Cell Values in Bone Marrow on the Survival of Patients with Multiple Myeloma-A Single-Center Observational Study.Journal of clinical medicine · 2025Article
- Associations of ANGPT2 expression and its variants (rs1868554 and rs7825407) with multiple myeloma risk and outcome.Frontiers in oncology · 2025Article
- Anti-Angiogenic Activity of Drugs in Multiple Myeloma.Cancers · 2023Review
- Review
- What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma.Targeted oncology · 2022Review
- Article
- The Impact of Induction Regimes on Immune Responses in Patients with Multiple Myeloma.Cancers · 2021Review
- Xanthomicrol Exerts Antiangiogenic and Antitumor Effects in a Mouse Melanoma (B16F10) Allograft Model.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Multiple Myeloma and Bone: The Fatal Interaction.Cold Spring Harbor perspectives in medicine · 2018Review
- Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing.Current osteoporosis reports · 2017Review
- Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.Cellular and molecular life sciences : CMLS · 2016Review
- A DNA-binding Molecule Targeting the Adaptive Hypoxic Response in Multiple Myeloma Has Potent Antitumor Activity.Molecular cancer research : MCR · 2016Article
- Immunohistochemical expression of endoglin offers a reliable estimation of bone marrow neoangiogenesis in multiple myeloma.Journal of cancer research and clinical oncology · 2015Article
- Thalidomide influences atherogenesis in aortas of ApoE(-/-)/LDLR (-/-) double knockout mice: a nano-CT study.The international journal of cardiovascular imaging · 2014Article
- Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.Leukemia & lymphoma · 2013Review
- Article
- Angiogenesis and multiple myeloma.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Bone marrow (BM) angiogenesis is increased in multiple myeloma and is an important prognostic factor for survival. Previous studies have shown that BM angiogenesis does not change following chemotherapy or stem cell transplant. Given its potential antiangiogenic effect, we evaluated if thalidomide therapy would affect the BM microvessel density (MVD). We studied BM angiogenesis in 81 patients with various disease stages treated with thalidomide with or without dexamethasone. MVD was determined as previously described. MVD was compared between pretreatment marrows and those obtained 4-6 months following therapy. The median (range) MVD pretherapy was 28 (2-116) and post-therapy was 15 (3-97). A partial or complete response was seen in 58% of patients, stable disease in 41% and progressive disease in one patient. MVD decreased significantly in responders (median decrease of 12, P<0.001). In contrast, no significant change in MVD was seen in those failing to respond to thalidomide. Unlike the lack of resolution of angiogenesis reported with other therapies, we demonstrate for the first time a significant decrease in microvessels with thalidomide therapy. Although not conclusive, this result lends further support to the hypothesis that angiogenesis is a relevant therapeutic target in myeloma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.